A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance)
Publication
, Conference
Halabi, S; Luo, B; Guo, SS; Knutson, T; Lyman, J; Kobilka, A; Beltran, H; Antonarakis, ES; Rosenberg, JE; Galsky, MD; Ryan, CJ; Kelly, WK ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Halabi, S., Luo, B., Guo, S. S., Knutson, T., Lyman, J., Kobilka, A., … Armstrong, A. J. (2024). A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Halabi, Susan, Bin Luo, Siyuan S. Guo, Todd Knutson, Jacqueline Lyman, Anna Kobilka, Himisha Beltran, et al. “A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.
Halabi S, Luo B, Guo SS, Knutson T, Lyman J, Kobilka A, et al. A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance). In: JOURNAL OF CLINICAL ONCOLOGY. 2024.
Halabi, Susan, et al. “A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.
Halabi S, Luo B, Guo SS, Knutson T, Lyman J, Kobilka A, Beltran H, Antonarakis ES, Rosenberg JE, Galsky MD, Ryan CJ, Kelly WK, Small EJ, Morris MJ, Dehm SM, Armstrong AJ. A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance). JOURNAL OF CLINICAL ONCOLOGY. 2024.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2024
Volume
42
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences